Perception of risk: the state of COX-2 selective inhibitors.

被引：2
|
作者：
Simon L.S. [1 ]
Strand V. [1 ]
机构：
[1] Harvard Medical School, Beth Israel Deaconess Medical Center, Suite 5A, 110 Francis Street, Boston, 02115, MA
来源：
Current Rheumatology Reports | 2005年 / 7卷 / 3期
关键词：
Celecoxib; Naproxen; Rofecoxib; Etoricoxib; Valdecoxib;
D O I：
10.1007/s11926-996-0032-4
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：163 / 166
页数：3
相关论文
共 50 条
  • [1] Structure based design of selective COX-2 inhibitors.
    Browner, MF
    FASEB JOURNAL, 1998, 12 (08): : A1304 - A1304
  • [2] Computational approach to find selective COX-2 inhibitors.
    Kumar, M
    Zauhar, RJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U528 - U528
  • [3] Discovery of new class of potent and selective COX-2 inhibitors.
    Wang, Z
    Black, WC
    Brideau, C
    Chan, C
    Charleson, S
    Cromlish, W
    Denis, D
    Ethier, D
    Evans, J
    Falgueyret, JP
    FordHutchinson, A
    Gauthier, JY
    Gordon, R
    Greig, G
    Gresser, M
    Grimm, E
    Guay, J
    Leblanc, Y
    Leger, S
    Kargman, S
    Mancini, J
    ONeill, G
    Ouellet, M
    Percival, D
    Prasit, P
    Riendeau, D
    Rodger, I
    Skorey, K
    Tagari, P
    Therien, M
    Wong, E
    Young, RN
    Xu, L
    Zamboni, R
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 212 : 16 - MEDI
  • [4] Potent, selective, and orally active second generation COX-2 inhibitors.
    Roy, PJ
    Brideau, C
    Chan, C
    Charleson, S
    Cromlish, W
    Ethier, D
    Evans, J
    Ford-Hutchinson, A
    Greig, G
    Gresser, M
    Grimm, E
    Guay, J
    Kargman, S
    Leblanc, Y
    Li, CS
    O'Neill, G
    Riendeau, D
    Rodger, I
    Wang, Z
    Wong, E
    Xu, L
    Young, RN
    Zamboni, R
    Prasit, P
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 215 : U861 - U861
  • [5] Cellular mitogenesis is inhibited by selective cyclooxygenase-2 (COX-2) inhibitors.
    Longo, W
    Erickson, B
    Mazuski, J
    Panesar, N
    Deshpande, Y
    Kaminski, D
    GASTROENTEROLOGY, 1998, 114 (04) : A636 - A636
  • [6] Selective inhibitors of COX-2
    不详
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1996, 6 (01) : 79 - 80
  • [7] Risk of hyperkalemia associated with selective COX-2 inhibitors
    Aljadhey, Hisham
    Tu, Wanzhu
    Hansen, Richard A.
    Blalock, Susan
    Brater, Craig
    Murray, Michael D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (11) : 1194 - 1198
  • [8] Selective COX-2 inhibitors
    Parnham, MJ
    DRUG NEWS & PERSPECTIVES, 1997, 10 (03) : 182 - 187
  • [9] Selective COX-2 inhibitors and risk of myocardial infarction
    Krötz, F
    Schiele, TM
    Klauss, V
    Sohn, HY
    JOURNAL OF VASCULAR RESEARCH, 2005, 42 (04) : 312 - 324
  • [10] Rofecoxib, selective COX-2 inhibitors and cardiovascular risk
    Dhaun, N.
    Maxwell, S. R. J.
    Webb, D. J.
    JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 2005, 35 (02): : 101 - 103
12345